• Explore /
  • Poster
  • / Phase II trial of palbociclib (PD-0332991) in patients with metastatic urothelial cancer (UC) after failure of first-line chemotherapy.

Phase II trial of palbociclib (PD-0332991) in patients with metastatic urothelial cancer (UC) after failure of first-line chemotherapy.

Abstract Poster

Authors

Tracy Rose

Tracy Lynn Rose

University of North Carolina Hospital, Chapel Hill, NC

Tracy Lynn Rose , David D. Chism , Ajjai Shivaram Alva , Allison Mary Deal , Susan Maygarden , Young E. Whang , Jordan Kardos , Anthony Drier , William Y. Kim , Matthew I. Milowsky

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers

Track

Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers

Sub Track

Urothelial Carcinoma

Clinical Trial Registration Number

NCT02334527

Citation

J Clin Oncol 36, 2018 (suppl 6S; abstr 500)

DOI

10.1200/JCO.2018.36.6_suppl.500

Abstract #

500

Poster Bd #

K7

Abstract Disclosures

Similar Posters

Poster

2014 Genitourinary Cancers Symposium

Somatic genomic alterations in urothelial cancer: Results of the Cancer Genome Atlas (TCGA) bladder cancer (BC) analysis.

Somatic genomic alterations in urothelial cancer: Results of the Cancer Genome Atlas (TCGA) bladder cancer (BC) analysis.

First Author: Jonathan E. Rosenberg

First Author: Kevin R Reyes

First Author: Phillip Lee Palmbos

First Author: Elisa Agostinetto